No data to show
XSTO
ELIC
Market cap26mUSD
Jul 14, Last price
5.29SEK
1D
1.73%
1Q
57.91%
IPO
-9.18%
Name
Elicera Therapeutics AB
Chart & Performance
P/E
—
P/S
36.02
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.28%
Rev. gr., 5y
%
Revenues
7m
-36.52%
Net income
-16m
L-1.75%
CFO
-23m
L+57.23%
Profile
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 7,128 -36.52% | 11,230 777.23% | 1,280 217,987.39% | |||||||
Cost of revenue | 12 | |||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 7,128 | 11,230 | 1,268 | |||||||
NOPBT Margin | 100.00% | 100.00% | 99.08% | |||||||
Operating Taxes | 76 | |||||||||
Tax Rate | 5.98% | |||||||||
NOPAT | 7,128 | 11,230 | 1,193 | |||||||
Net income | (16,110) -1.75% | (16,398) -15.97% | (19,515) 48.72% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 20,479 | |||||||||
BB yield | -38.84% | |||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (1) | |||||||||
Net debt | (26,399) | (29,384) | (44,306) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (23,463) | (14,923) | (8,571) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 483 | |||||||||
Cash from financing activities | 20,479 | |||||||||
FCF | 7,128 | 11,230 | 1,193 | |||||||
| Balance | ||||||||||
Cash | 26,399 | 29,383 | 43,822 | |||||||
Long term investments | 1,000 | 484 | ||||||||
Excess cash | 26,043 | 28,822 | 44,242 | |||||||
Stockholders' equity | (65,852) | (50,385) | (33,987) | |||||||
Invested Capital | 86,623 | 66,787 | 66,781 | |||||||
ROIC | 9.29% | 16.82% | 1.79% | |||||||
ROCE | 34.32% | 68.47% | 3.87% | |||||||
| EV | ||||||||||
Common stock shares outstanding | 31,570 | 19,782 | 19,782 | |||||||
Price | 1.67 -63.38% | 4.56 29.73% | 3.52 -29.98% | |||||||
Market cap | 52,721 -41.55% | 90,206 29.73% | 69,534 -13.10% | |||||||
EV | 26,322 | 60,822 | 25,227 | |||||||
EBITDA | 7,140 | 11,242 | 1,280 | |||||||
EV/EBITDA | 3.69 | 5.41 | 19.71 | |||||||
Interest | 129 | |||||||||
Interest/NOPBT | 10.20% | |||||||||